CANCER SURGERY:
A COMPLETE PATIENT GUIDE

Surgery is simultaneously the oldest and most technically sophisticated treatment in oncology. The goal of every cancer operation — curative, cytoreductive, or palliative — fundamentally shapes how aggressive the procedure should be, what risks are acceptable, and how outcomes are measured.

“A tumour is resectable when complete removal is technically feasible, the patient is fit to tolerate the procedure, and the expected oncological benefit justifies the operative risk.”

• Curative Surgery

  All visible and microscopic tumour is removed with the intent of achieving long-term cure or disease-free survival. Requires the highest technical skill, clear margins, and often combines with neoadjuvant or adjuvant therapy. Resectability is assessed by surgical oncologists at multidisciplinary tumour board review.

• Cytoreductive (Debulking) Surgery

  When complete removal is impossible, surgical debulking reduces disease burden to improve the efficacy of subsequent systemic therapy or radiation. Ovarian cancer exemplifies this approach — aggressive cytoreduction to no visible residual disease (R0) is the strongest predictor of chemotherapy response and survival.

• Palliative Surgery

  Performed to relieve symptoms or prevent life-threatening complications — not to extend life substantially. Examples: colostomy to bypass an obstructing rectal cancer, biliary stenting for jaundice, vertebral stabilisation for spinal metastases. Improves quality of life when systemic treatment is the primary strategy.

• Preventive and Diagnostic Surgery

  Prophylactic operations (e.g., risk-reducing mastectomy for BRCA1/2 carriers, colectomy for familial adenomatous polyposis) prevent cancer in high-risk individuals. Diagnostic biopsy — core needle, incisional, or excisional — establishes tissue diagnosis and molecular profiling before any treatment begins.

Cancer surgery spans a spectrum from a fine-needle aspirate under image guidance to multi-organ resections lasting ten or more hours. Understanding the vocabulary of surgical oncology helps patients engage meaningfully with their surgical team.

• Biopsy (FNA, Core Needle, Incisional, Excisional)

  Establishes tissue diagnosis before treatment. FNA provides cytology only; core needle biopsy provides histological architecture adequate for most molecular testing. Excisional biopsy removes the entire lesion — diagnostic and potentially therapeutic for small, accessible tumours.

• Segmentectomy / Partial Resection

  Removal of a segment or portion of an organ — hepatic segmentectomy, lung segmentectomy, wide local excision of breast or skin. Preserves organ function while achieving complete tumour removal with clear margins.

• Lobectomy / Major Resection

  Removal of a lobe (pulmonary lobectomy for lung cancer, thyroid lobectomy) or major organ segment. The standard curative procedure for early-stage lung cancer; widely performed via VATS or robotic approach at high-volume centres.

• Radical / Multi-Organ Resection

  Radical procedures — Whipple (pancreaticoduodenectomy), total gastrectomy with D2 lymphadenectomy, radical cystectomy, radical prostatectomy — remove the primary tumour en bloc with adjacent structures and lymph node basins. Require specialist high-volume surgical teams.

Margin status — whether cancer cells are present at the cut edge of the resected specimen — is the strongest predictor of local recurrence and a major determinant of whether adjuvant radiation is required.

“R0 resection — no residual microscopic tumour at any margin — is the standard against which every curative-intent cancer operation is measured.”

• Margin Classification

  R0: no tumour at the resection margin (clear). R1: microscopic tumour at the margin (positive). R2: macroscopic residual tumour left in situ. R0 is the target for all curative operations — R1 or R2 resection substantially increases local recurrence risk and often mandates re-excision or intensified adjuvant therapy.

• Site-Specific Margin Standards

  Breast cancer: "no ink on tumour" — wider margins do not improve local control when radiotherapy is given. Colorectal: circumferential radial margin (CRM) ≥ 1mm is the standard; CRM involvement predicts locoregional failure and reduced survival. Soft tissue sarcoma: wider margins (≥10mm) are required due to the high local recurrence rate of myxoid and high-grade sarcomas.

Regional lymph nodes are the first site of spread for most solid tumours. Whether and how extensively to address them surgically is one of the most nuanced and evolving areas in surgical oncology — balancing accurate staging against the morbidity of full nodal dissection.

• Sentinel Lymph Node Biopsy (SLNB)

  SLNB identifies and removes only the first draining lymph node(s) from the primary tumour. If the sentinel node is cancer-free, downstream nodes are almost always clear — avoiding full lymphadenectomy and its complications (lymphedema, nerve injury). Standard for clinically node-negative breast cancer and melanoma staging.

• Formal Lymphadenectomy

  Complete removal of all nodes in a defined anatomical region — D2 gastrectomy (dissection of perigastric + major vessel nodal stations), pelvic lymphadenectomy for gynaecological/urological cancers, axillary clearance for node-positive breast cancer. Required where nodal clearance has therapeutic benefit or where accurate staging demands multiple nodes.

The shift from open to minimally invasive surgery has transformed cancer surgery over 30 years. For most cancer types, laparoscopic or robotic approaches achieve equivalent oncological outcomes with substantially better perioperative recovery.

Each tumour site has its own surgical subspecialty, evidence base, and technical requirements. This table summarises the standard curative procedures and key surgical considerations by cancer type.

Modern cancer surgery rarely operates in isolation. The sequence of surgery, chemotherapy, radiation, and targeted therapy is precisely choreographed by a multidisciplinary tumour board based on tumour biology, staging, and treatment goal.

• Neoadjuvant Therapy (Before Surgery)

  Chemotherapy, radiation, or targeted therapy given before surgery to shrink the primary tumour (downstage), eliminate micrometastatic disease, and convert borderline-resectable tumours to resectable. Standard neoadjuvant regimens: FLOT for gastric cancer, capecitabine + radiation for rectal cancer (enabling TME), carboplatin + paclitaxel for oesophageal cancer, FOLFIRINOX for borderline-resectable pancreatic cancer.

• Adjuvant Therapy (After Surgery)

  Treatment given after surgery when no visible tumour remains, targeting microscopic residual disease. Adjuvant chemotherapy, radiation, hormonal therapy, targeted therapy, and immunotherapy are used in different combinations by tumour type — e.g., FOLFOX for stage III colorectal cancer, trastuzumab for HER2+ breast cancer, osimertinib for EGFR-mutant resected NSCLC, and nivolumab for oesophageal cancer after CRT and surgery.

• R0Clear Margin TargetNo tumour at any resection margin the universal measure of surgical success in curative-intent oncology.
• 70%Liver Volume RemovableThe liver's regenerative capacity allows resection of up to 70% of its volume in patients with healthy underlying liver function.
• ≥15Lymph Nodes for D2Minimum lymph nodes required for adequate D2 gastrectomy staging — the quality benchmark for gastric cancer surgery.
• 3–10%Anastomotic Leak RateReported range for anastomotic leak after colorectal and oesophageal resection at specialist centres — the most feared surgical complication.
• 60%Textbook outcome in high-volume rectal cancer surgeryA composite quality benchmark that includes R0 resection, adequate lymph node yield, no major complication, no readmission, and timely recovery.
• 4.5Median hospital stay after ERAS colorectal cancer surgeryEnhanced Recovery After Surgery (ERAS) protocols have shortened postoperative stay substantially, showing how modern oncologic surgery is becoming safer, faster, and more standardized.

Cancer surgery frequently requires removal of tissue, organs, or structures that affect appearance, function, and quality of life. Reconstructive surgery — often performed simultaneously with tumour resection in a combined oncoplastic approach — aims to restore as much of what was removed as is surgically feasible.

• Breast Reconstruction

  Immediate or delayed reconstruction after mastectomy. Options: implant-based (tissue expanders + permanent implant — simpler, shorter surgery), autologous flap (DIEP flap using abdominal tissue — longer surgery, more natural result, no implant). Nipple-sparing mastectomy with immediate implant reconstruction is the preferred approach at high-volume centres for appropriately staged tumours.

• Head and Neck Reconstruction

  Head and neck surgery — oral cavity, pharynx, larynx, thyroid — can cause functional deficits in speech, swallowing, and breathing. Microsurgical free flap reconstruction (fibula free flap for mandible, anterolateral thigh flap for soft tissue defects) restores anatomy and function. Requires combined surgical oncology and reconstructive microsurgery teams.

• Urological Reconstruction

  Total cystectomy for bladder cancer requires urinary diversion: ileal conduit (urine drains into an external bag — reliable and durable) or orthotopic neobladder (bowel segment reconstructed into a new bladder allowing spontaneous voiding — higher quality of life, greater surgical complexity). Neobladder requires careful patient selection and compliance with self-catheterisation protocol.

• Colorectal Reconstruction

  Total mesorectal excision for low rectal cancer may require coloanal anastomosis (restoring bowel continuity) or permanent end colostomy when tumour location makes anastomosis unsafe. Temporary defunctioning ileostomy protects the anastomosis and is reversed after healing. Stoma education and support are integral to the perioperative care pathway.

The outcome of cancer surgery is not determined solely in the operating theatre. What happens in the weeks before surgery and the days and weeks after are equally important determinants of recovery, complication rates, and how quickly the patient reaches adjuvant therapy.

1. 1

   Prehabilitation (2–6 Weeks Before Surgery)

   Structured exercise, nutritional optimisation (high-protein diet), smoking cessation, and anaemia correction before major surgery. Prehabilitation improves cardiorespiratory reserve, reduces postoperative complications, and shortens hospital stay.

2. 2

   Preoperative Preparation (Day Before)

   ERAS protocols replace prolonged fasting with carbohydrate loading drinks up to 2 hours before anaesthesia — reducing insulin resistance and muscle catabolism. Bowel preparation is no longer routinely required for most colorectal operations.

3. 3

   Surgery and Intraoperative Care

   Goal-directed fluid therapy, cell salvage (reprocessing shed blood for retransfusion), multimodal analgesia to minimise opioids, and minimally invasive approach where feasible. Frozen section analysis confirms margin status intraoperatively.

4. 4

   Early Recovery (Days 1–3)

   Early mobilisation (out of bed day 1), early oral intake (sips day 1, free fluids day 2), urinary catheter removal day 1–2, multimodal analgesia with regional blockade (epidural or TAP block). Drains removed when output is low and non-bloody.

5. 5

   Hospital Discharge and Home Recovery

   Most major cancer operations discharge in 3–7 days with ERAS protocols — compared to 10–14 days with traditional care. Discharge criteria: adequate pain control on oral analgesia, tolerating oral diet, mobile, wound secure. District nurse follow-up arranged before discharge.

6. 6

   Pathology Review and Adjuvant Planning

   Final pathology report confirms margin status, lymph node involvement, tumour grade, and molecular features within 7–14 days of surgery. Multidisciplinary tumour board review determines adjuvant chemotherapy, radiation, targeted therapy, or hormonal therapy plan.

Informed consent for cancer surgery requires understanding the specific complications relevant to each procedure. Modern surgical centres manage these through early recognition, structured response protocols, and specialist support teams.

The evidence that surgical volume — at both the hospital and individual surgeon level — determines outcomes is overwhelming. Choosing where and by whom cancer surgery is performed is among the most consequential decisions a patient will make.

“Hospitals performing the highest volumes of a specific cancer operation consistently achieve lower mortality, fewer complications, higher R0 rates, and in many tumour types, longer survival.”

• The Volume-Outcome Relationship

  Across virtually every major cancer operation, higher-volume centres achieve better outcomes. For Whipple procedure: 90-day mortality 1–2% at volume centres vs 5–10% at low-volume hospitals. For oesophagectomy: anastomotic leak 5–8% vs 15–20%. For D2 gastrectomy: 5-year survival differences of 10–15% between high- and low-volume centres.

• Multidisciplinary Tumour Board Review

  The multidisciplinary tumour board (MDT) — surgical oncologist, medical oncologist, radiation oncologist, radiologist, and pathologist reviewing the case together — determines the optimal treatment sequence. Every patient with cancer should have their case reviewed at an MDT before surgery is undertaken. This single step is the most important quality indicator.

China and India offer world-class surgical oncology — particularly for gastric, liver, lung, and colorectal cancer — at 40–70% lower cost than the USA or Western Europe, without compromising surgical volume or technical expertise.

Explore dedicated short-form pages addressing specific surgical questions from margin terminology to HIPEC candidacy and accessing cancer surgery in China.

Frequently Asked Questions About Cancer Surgery